Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023.
- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023.
- In the fourth quarter, Edwards remained focused on its key value drivers to unlock the significant long-term opportunity for patients: a portfolio of differentiated therapies; positive clinical trial results to support approvals and adoption; and favorable real-world clinical outcomes.
- Research and development expenses in the fourth quarter grew 16 percent over the prior year to $270 million, or 17.6 percent of sales.
- During the fourth quarter, the company repurchased $444 million of stock through a combination of a pre-established trading plan and accelerated share repurchase programs.